[187 Pages Report] Sales in the global HDL Cholesterol Kits Market are slated to top US$ 568.1 Million in 2022. Expanding at a healthy 4.8% CAGR, the market size is projected to total US$ 786.2 Million by 2029.
| Attributes | Details |
|---|---|
| HDL Cholesterol Kits Market Estimated Size 2022 | US$ 568.1 Million |
| HDL Cholesterol Kits Market Value-based CAGR (2022 to 2029) | 4.8% |
| HDL Cholesterol Kits Market Size in Projected 2029 | US$ 786.2 Million |
The increasing adoption of an unhealthy diet, rising cases of obesity, and lack of physical activities as life gets more hectic will result in a higher prevalence of cholesterol. Consequently, the demand for HDL cholesterol kits is expected to increase in the coming years.
The consumption of certain medications for the treatment of health problems such as high blood pressure, organ transplants, acne, HIV/AIDS, cancer, and irregular heart rhythms can also lead to the occurrence of HDL cholesterol.
Drinking too much alcohol, smoking cigarettes, and eating full-fat dairy products and fatty cuts of meat may raise an individual’s total cholesterol level. Thanks to awareness programs conducted by government bodies, the general public is better educated about the consequences of high cholesterol levels, such as the development of stroke, heart attack, or chest pain.
These factors are therefore expected to spur the sales of HDL cholesterol test kits.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
| Particulars | Details |
|---|---|
| H1, 2021 | 4.70% |
| H1, 2022 Projected | 4.75% |
| H1, 2022 Outlook | 4.65% |
| BPS Change - H1, 2022 (O) - H1, 2022 (P) | (-) 10 ↓ |
| BPS Change - H1, 2022 (O) - H1, 2021 | (-) 05 ↓ |
The comparative analysis and market growth rate of the global HDL cholesterol kits market as studied by Future Market Insights will show a negative BPS growth in the H1-2022 outlook as compared to H1-2022 projected period by 10 BPS, and a decline in the BPS values is expected in H1-2022 over H1- 2021 duration with 05 Basis Point Share (BPS).
The drop in the BPS values is associated with the development of home test kits, however, the adoption of these products is limited because of the high costs associated with the product, and their inefficiency in providing an accurate diagnosis. Moreover, the home test kits are not easily comprehensible, and thus detain the future adoption of HDL cholesterol kits in the future.
Conversely, the advent of several regional government initiatives in the regions of Asia Pacific for comprehensive diagnosis and point-of-care for infectious and chronic diseases will subsequently present positive outcomes for market growth over the forecasted years.
The market is subject to regulatory impositions and product adoption rate, as per the macro and industry standards. The key developments in the market include product revamp strategies that incorporate an electronic meter within the test kits.
The HDL cholesterol kits market is expected to register a 4.8% CAGR between 2022 and 2029, up from a 4.0% CAGR recorded from 2014 to 2021, predicts Future Market Insights.
The soaring need for the prompt determination of a person’s risk for stroke or heart disease is likely to propel the demand for HDL cholesterol level kits in the forthcoming years. This is mainly happening because of the surging geriatric population across the globe who are at a high risk of developing severe heart conditions.
As per the World Population Prospects 2019 published by the United Nations (UN), 1 in 6 people in the world will be over the age of 65 years by 2050, up from 1 in 11 in 2019. The organization further revealed that in 2019 there were approximately 703 million individuals belonging to the age group of 65 years and above in the world. In 2050, this number is estimated to double to 1.5 billion.
Thus, the increasing geriatric population in various parts of the globe is set to bolster the sales of HDL cholesterol test kits in the forthcoming years.
Uncontrolled diabetes, untreated hypothyroidism, liver disease, high sugar intake, and low or high-fat percentage in the body are some of the other crucial factors that are anticipated to negatively affect a person’s level of cholesterol. These factors are projected to increase the need for timely cholesterol testing and help in propelling the sales of novel kits.
The rising prevalence of diabetes is expected to propel the demand for HDL cholesterol level test kits in the forecast period. Diabetic dyslipidemia is often linked with elevated levels of LDL cholesterol and lower levels of HDL cholesterol. As changing cholesterol levels can cause heart disease even with well-controlled blood glucose levels, healthcare professionals recommend diabetic patients enhance their coronary health by lowering their cholesterol levels.
According to the International Diabetes Federation (IDF), around 537 million adults belonging to the age group of 20 to 79 years were living with diabetes in 2021. It is projected to reach 783 million by 2045 and 643 million by 2030. Also, 1 in 6 live births is impacted by diabetes during pregnancy. These trends are estimated to continue in the near future and augment the sales of HDL cholesterol detection kits.
Many research and educational institutions are conducting extensive Research and Development activities to discover new approaches for treating diabetes and other associated conditions. Some of the others are trying to investigate the risk factors of diabetic dyslipidemia.
For instance, in October 2018, the National Institute for Nutrition and Health found that the prevalence of dyslipidemia was 59.3%, 46.8%, and 39.9% in individuals with Type 2 Diabetes Mellitus (T2DM), prediabetes, and normal glucose, respectively. Hence, the rising prevalence of this condition among people worldwide is expected to bolster the sales of innovative kits.
Principal Consultant
“Increasing Obesity Cases to Drive Sales of HDL Cholesterol Test Kits”
The surging cases of obesity in the USA owing to the rapid adoption of sedentary lifestyles and the increasing consumption of junk food are anticipated to propel the demand for HDL cholesterol test kits in North America. The sales of home test kits are likely to rise as body weight has a direct association with cardiovascular risk factors, such as high and low cholesterol.
As per the Centers for Disease Control and Prevention (CDC), from 2017 to 2018, the prevalence of obesity was 42.4% in the USA The organization further mentioned that medical costs for people who were affected by obesity were $1,429 higher than medical costs for those with a healthy weight. Thus, the increasing risk of developing obesity-related conditions is projected to compel people to get their medical tests done from time to time, which would propel the sales of HDL cholesterol detection kits in the USA
“Prevalence of Hypothyroidism to Bolster Demand for HDL Cholesterol Level Test Kits”
The increasing prevalence of hypothyroidism among people in the UK is estimated to drive the demand for HDL cholesterol level test kits in Europe over the forthcoming years. Radiation therapy, certain medications containing lithium compounds, thyroid surgery, and the occurrence of autoimmune disorders are some of the major causes of hypothyroidism.
According to the National Institute for Health and Care Excellence (NICE), hypothyroidism is found in more than 5% of the UK population over the age of 60. Compared to men, women are 5 to 10 times more likely to be affected by this condition. These numbers are expected to surge in the upcoming years, thereby driving the market in the UK
“Surging Government Funding in Healthcare to Spur Sales of HDL Cholesterol Detection Kits”
The rising demand for cholesterol testing in China because of the need to prevent chronic diseases is projected to push the sales of HDL cholesterol detection kits in East Asia. The growing awareness about the significance of regular healthcare testing among people is another factor that is set to surge sales in China.
The high healthcare expenditure and the ongoing development of the healthcare infrastructure in this country are anticipated to bode well for the market. In 2018, for instance, China spent about 6.6% of its GDP on healthcare, which amounts to US$ 1,665 billion. Out of this, 28% was paid out-of-pocket, 44% was financed by social health donations, private health insurance, or publicly funded health insurance, and 28% was financed by the local and central governments. Hence, increasing government support in terms of funding in this country is projected to accelerate the market.
“HDL and LDL/VLDL Cholesterol Level Kits to Be in High Demand among CVD Patients”
Based on product type, the HDL and LDL/VLDL assay kit segment is likely to dominate the HDL cholesterol kits market in the near future. The rising prevalence of lifestyle disorders, such as Cardiovascular Disease (CVD) globally owing to the higher adoption of a sedentary culture and the lack of time to prepare healthy meals is anticipated to fuel the sales of HDL and LDL/VLDL cholesterol level kits.
As per the World Health Organization (WHO), in 2019, around 17.9 million people died from CVDs, thereby exhibiting 32% of all global deaths. The organization also stated that CVD can be prevented by eliminating the harmful use of alcohol and tobacco, physical inactivity, and the adoption of an unhealthy diet. This trend is set to continue in the forecast period, thereby propelling the segment’s growth.
“Availability of Advanced HDL Cholesterol Test Kits in Hospitals to Continue Increasing”
In terms of end users, the hospital's segment is projected to remain at the forefront by accounting for 50.1% of the HDL cholesterol kits market share in 2022, estimated by FMI. The ongoing development of cutting-edge hospitals equipped with technologically advanced medical testing products, such as HDL cholesterol test kits is anticipated to drive the segment.
On the other hand, the diagnostic labs and clinics segments are estimated to generate approximately 31.3% and 18.6% of the market share in 2022, respectively. The cost-effectiveness of laboratory testing and the ability of clinics to provide urgent medical attention to those who require it are likely to bolster both segments.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Key players operating in the HDL cholesterol kits market are focusing on acquisitions and collaborations with international and regional companies to surge their sales and attract large consumer bases across the globe.
Meanwhile, some of the other HDL cholesterol level kit manufacturers are aiming to broaden their global presence by opening new manufacturing facilities and signing distribution agreements with firms located in developed, as well as emerging markets of Europe, the Middle East, and Asia Pacific. A few of the players are engaging in the development of point-of-care testing as it is convenient and helpful for making quick decisions.
For instance,
| Attributes | Details |
|---|---|
| Forecast Period | 2014 to 2021 |
| Historical Data Available for | 2022 to 2029 |
| Market Analysis | Units for Volume and US$ Million for Value |
| Key Regions Covered | North America; Latin America; Europe; East Asia; South Asia; Oceania; and the Middle East & Africa (MEA). |
| Key Countries Covered | United States, Canada, Brazil, Mexico, Germany, UK, France, Italy, Spain, Nordic, Russia, Poland, China, India, Thailand, Indonesia, Australia and New Zealand, Japan, GCC countries, North Africa, South Africa, and others. |
| Key Market Segments Covered | Product Type, End User, and Region |
| Key Companies Profiled | Diazyme Laboratories, Inc.; Randox Laboratories Limited; Fujifilm Holding Corporation; Thermo Fisher Scientific; Abcam plc.; Merck KGaA; Abbott Laboratories; Danaher Corporation; PerkinElmer, Inc.; Hoffmann-La Roche Ltd. |
| Pricing | Available upon Request |
The global HDL cholesterol kits market is expected to reach a valuation of US$ 568.1 Million in 2022.
The global HDL cholesterol kits market grew at a healthy 4.0% CAGR between 2014 and 2021.
The increasing prevalence of diabetes and the rising alcohol consumption are the key trends boosting the sales of HDL cholesterol kits.
Diazyme Laboratories, Inc., Randox Laboratories Limited, Fujifilm Holding Corporation, Thermo Fisher Scientific, Abcam plc, Merck KGaA, and Abbott Laboratories are some of the leading players present in the global HDL cholesterol kits market.
The hospital segment is anticipated to account for 50.1% of the HDL cholesterol kits market share in 2022.
The clinic's end-user segment is projected to account for 18.6% of the HDL cholesterol kits market share in the forecast period.
1. Executive Summary | HDL Cholesterol Kits Market
1.1. Global Market Outlook
1.2. Market Trends
1.3. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Key Market Trends
3.1. Key Trends Impacting the Market
3.2. Product Innovation / Development Trends
4. Global Market (Size in US$ Million) Analysis 2014 to 2021 and Forecast, 2022 to 2029
4.1. Historical Market Value (US$ Million) Analysis, 2014 to 2021
4.2. Current and Future Market Value (US$ Million) Projections, 2022 to 2029
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Market Background
5.1. Macro-Economic Factors
5.1.1. Global GDP Growth Outlook
5.1.2. Global Industry Value Added
5.1.3. Healthcare Expenditure and Sector Outlook
5.2. Forecast Factors - Relevance & Impact
5.3. Market Dynamics
5.3.1. Drivers
5.3.2. Restraints
5.3.3. Opportunity
6. Global Market Analysis 2014 to 2021 and Forecast 2022 to 2029, By Product Type
6.1. Introduction / Key Findings
6.2. Historical Market Size (US$ Million) Analysis By Product Type, 2014 to 2021
6.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Product Type, 2022 to 2029
6.3.1. HDL Cholesterol Precipitating Reagent Kit
6.3.2. HDL Cholesterol Direct Reagent Kit
6.3.3. HDL and LDL/VLDL Assay Kit
6.4. Market Attractiveness Analysis By Product Type
7. Global Market Analysis 2014 to 2021 and Forecast 2022 to 2029, By End User
7.1. Introduction / Key Findings
7.2. Historical Market Size (US$ Million) Analysis By End User, 2014 to 2021
7.3. Current and Future Market Size (US$ Million) Analysis and Forecast By End User, 2022 to 2029
7.3.1. Hospitals
7.3.2. Clinics
7.3.3. Diagnostic Laboratories
7.4. Market Attractiveness Analysis By End User
8. Global Market Analysis 2014 to 2021 and Forecast 2022 to 2029, By Region
8.1. Introduction
8.2. Historical Market Size (US$ Million) Analysis By Region, 2014 to 2021
8.3. Current Market Size (US$ Million) Analysis and Forecast By Region, 2022 to 2029
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. East Asia
8.3.5. South Asia
8.3.6. Oceania
8.3.7. Middle East & Africa (MEA)
8.4. Market Attractiveness Analysis By Region
9. North America Market Analysis 2014 to 2021 and Forecast 2022 to 2029
9.1. Introduction
9.2. Historical Market Size (US$ Million) Trend Analysis By Market Taxonomy, 2014 to 2021
9.3. Market Size (US$ Million) Forecast By Market Taxonomy, 2022 to 2029
9.3.1. By Country
9.3.1.1. The USA
9.3.1.2. Canada
9.3.2. By Product Type
9.3.3. By End User
9.4. Market Attractiveness Analysis
9.4.1. By Country
9.4.2. By Product Type
9.4.3. By End User
10. Latin America Market Analysis 2014 to 2021 and Forecast 2022 to 2029
10.1. Introduction
10.2. Historical Market Size (US$ Million) Trend Analysis By Market Taxonomy, 2014 to 2021
10.3. Market Size (US$ Million) Forecast By Market Taxonomy, 2022 to 2029
10.3.1. By Country
10.3.1.1. Brazil
10.3.1.2. Argentina
10.3.1.3. Mexico
10.3.1.4. Rest of Latin America
10.3.2. By Product Type
10.3.3. By End User
10.4. Market Attractiveness Analysis
10.4.1. By Country
10.4.2. By Product Type
10.4.3. By End User
11. Europe Market Analysis 2014 to 2021 and Forecast 2022 to 2029
11.1. Introduction
11.2. Historical Market Size (US$ Million) Trend Analysis By Market Taxonomy, 2014 to 2021
11.3. Market Size (US$ Million) Forecast By Market Taxonomy, 2022 to 2029
11.3.1. By Country
11.3.1.1. Germany
11.3.1.2. Italy
11.3.1.3. France
11.3.1.4. The UK
11.3.1.5. Spain
11.3.1.6. Rest of Europe
11.3.2. By Product Type
11.3.3. By End User
11.4. Market Attractiveness Analysis
11.4.1. By Country
11.4.2. By Product Type
11.4.3. By End User
12. East Asia Market Analysis 2014 to 2021 and Forecast 2022 to 2029
12.1. Introduction
12.2. Historical Market Size (US$ Million) Trend Analysis By Market Taxonomy, 2014 to 2021
12.3. Market Size (US$ Million) Forecast By Market Taxonomy, 2022 to 2029
12.3.1. By Country
12.3.1.1. China
12.3.1.2. Japan
12.3.1.3. South Korea
12.3.2. By Product Type
12.3.3. By End User
12.4. Market Attractiveness Analysis
12.4.1. By Country
12.4.2. By Product Type
12.4.3. By End User
13. South Asia Market Analysis 2014 to 2021 and Forecast 2022 to 2029
13.1. Introduction
13.2. Historical Market Size (US$ Million) Trend Analysis By Market Taxonomy, 2014 to 2021
13.3. Market Size (US$ Million) Forecast By Market Taxonomy, 2022 to 2029
13.3.1. By Country
13.3.1.1. India
13.3.1.2. Thailand
13.3.1.3. Indonesia
13.3.1.4. Malaysia
13.3.1.5. Singapore
13.3.1.6. Rest of South Asia
13.3.2. By Product Type
13.3.3. By End User
13.4. Market Attractiveness Analysis
13.4.1. By Country
13.4.2. By Product Type
13.4.3. By End User
14. Oceania Market Analysis 2014 to 2021 and Forecast 2022 to 2029
14.1. Introduction
14.2. Historical Market Size (US$ Million) Trend Analysis By Market Taxonomy, 2014 to 2021
14.3. Market Size (US$ Million) Forecast By Market Taxonomy, 2022 to 2029
14.3.1. By Country
14.3.1.1. Australia
14.3.1.2. New Zealand
14.3.2. By Product Type
14.3.3. By End User
14.4. Market Attractiveness Analysis
14.4.1. By Country
14.4.2. By Product Type
14.4.3. By End User
15. Middle East and Africa Market Analysis 2014 to 2021 and Forecast 2022 to 2029
15.1. Introduction
15.2. Historical Market Size (US$ Million) Trend Analysis By Market Taxonomy, 2014 to 2021
15.3. Market Size (US$ Million) Forecast By Market Taxonomy, 2022 to 2029
15.3.1. By Country
15.3.1.1. South Africa
15.3.1.2. GCC Countries
15.3.1.3. Turkey
15.3.1.4. Rest of Middle East and Africa
15.3.2. By Product Type
15.3.3. By End User
15.4. Market Attractiveness Analysis
15.4.1. By Country
15.4.2. By Product Type
15.4.3. By End User
16. Market Structure Analysis
16.1. Market Analysis by Tier of Companies
16.2. Market Share Analysis of Top Players
17. Competition Analysis
17.1. Competition Dashboard
17.2. Competition Deep Dive
17.2.1. Diazyme Laboratories, Inc.
17.2.1.1. Overview
17.2.1.2. Portfolio
17.2.1.3. Profitability by Market Segments (Solution/Region)
17.2.1.4. Regional Footprint
17.2.1.5. Strategy Overview
17.2.1.5.1. Marketing Strategy
17.2.1.5.2. Product Strategy
17.2.2. Randox Laboratories Limited
17.2.2.1. Overview
17.2.2.2. Portfolio
17.2.2.3. Profitability by Market Segments (Solution/Region)
17.2.2.4. Regional Footprint
17.2.2.5. Strategy Overview
17.2.2.5.1. Marketing Strategy
17.2.2.5.2. Product Strategy
17.2.3. Fujifilm Holding Corporation
17.2.3.1. Overview
17.2.3.2. Portfolio
17.2.3.3. Profitability by Market Segments (Solution/Region)
17.2.3.4. Regional Footprint
17.2.3.5. Strategy Overview
17.2.3.5.1. Marketing Strategy
17.2.3.5.2. Product Strategy
17.2.4. Thermo Fisher Scientific
17.2.4.1. Overview
17.2.4.2. Portfolio
17.2.4.3. Profitability by Market Segments (Solution/Region)
17.2.4.4. Regional Footprint
17.2.4.5. Strategy Overview
17.2.4.5.1. Marketing Strategy
17.2.4.5.2. Product Strategy
17.2.5. Abcam plc.
17.2.5.1. Overview
17.2.5.2. Portfolio
17.2.5.3. Profitability by Market Segments (Solution/Region)
17.2.5.4. Regional Footprint
17.2.5.5. Strategy Overview
17.2.5.5.1. Marketing Strategy
17.2.5.5.2. Product Strategy
17.2.6. Merck KGaA
17.2.6.1. Overview
17.2.6.2. Portfolio
17.2.6.3. Profitability by Market Segments (Solution/Region)
17.2.6.4. Regional Footprint
17.2.6.5. Strategy Overview
17.2.6.5.1. Marketing Strategy
17.2.6.5.2. Product Strategy
17.2.7. Abbott Laboratories
17.2.7.1. Overview
17.2.7.2. Portfolio
17.2.7.3. Profitability by Market Segments (Solution/Region)
17.2.7.4. Regional Footprint
17.2.7.5. Strategy Overview
17.2.7.5.1. Marketing Strategy
17.2.7.5.2. Product Strategy
17.2.8. Danaher Corporation
17.2.8.1. Overview
17.2.8.2. Portfolio
17.2.8.3. Profitability by Market Segments (Solution/Region)
17.2.8.4. Regional Footprint
17.2.8.5. Strategy Overview
17.2.8.5.1. Marketing Strategy
17.2.8.5.2. Product Strategy
17.2.9. PerkinElmer, Inc.
17.2.9.1. Overview
17.2.9.2. Portfolio
17.2.9.3. Profitability by Market Segments (Solution/Region)
17.2.9.4. Regional Footprint
17.2.9.5. Strategy Overview
17.2.9.5.1. Marketing Strategy
17.2.9.5.2. Product Strategy
17.2.10. Hoffmann-La Roche Ltd.
17.2.10.1. Overview
17.2.10.2. Portfolio
17.2.10.3. Profitability by Market Segments (Solution/Region)
17.2.10.4. Regional Footprint
17.2.10.5. Strategy Overview
17.2.10.5.1. Marketing Strategy
17.2.10.5.2. Product Strategy
18. Assumptions and Acronyms Used
19. Research Methodology
Explore Healthcare Insights
View Reports
HDL Cholesterol Kits Market
